Goldman Sachs
THRD

Goldman Sachs’s Third Harmonic Bio THRD Stock Holding History

Goldman Sachs’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-221,090
Closed -$1.2M – 6651
2025
Q2 		$1.2M Buy
221,090
+63,116
+40% +$315K ﹤0.01% 4559
2025
Q1 		$548K Buy
157,974
+51,307
+48% +$249K ﹤0.01% 5131
2024
Q4 		$1.1M Buy
106,667
+37,257
+54% +$464K ﹤0.01% 4758
2024
Q3 		$941K Buy
69,410
+33,098
+91% +$410K ﹤0.01% 4673
2024
Q2 		$472K Sell
36,312
-31,571
-47% -$391K ﹤0.01% 4866
2024
Q1 		$641K Buy
67,883
+51,661
+318% +$502K ﹤0.01% 4615
2023
Q4 		$178K Buy
+16,222
New +$129K ﹤0.01% 5189
2023
Q3 		– Sell
-16,460
Closed -$79.2K – 5852
2023
Q2 		$79.2K Buy
+16,460
New +$78.4K ﹤0.01% 5397
2022
Q4 		– Sell
-54,500
Closed -$1.03M – 6261
2022
Q3 		$1.03M Buy
+54,500
New +$982K ﹤0.01% 4478

Other funds holding THRD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AB
Amalgamated Bank New York $13.1B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs's THRD Position: Q3 2025 in Review

Goldman Sachs sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 221,090 shares — an estimated $1.2M sold.

Goldman Sachs first reported a position in THRD in Q3 2022 and held it in 9 quarters. The position peaked at $1.2M in Q2 2025. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • Goldman Sachs reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 221,090 Third Harmonic Bio shares in Q3 2025, an estimated $1.2M.
  • Goldman Sachs first reported a position in Third Harmonic Bio in Q3 2022 and held it in 9 quarters.
  • Goldman Sachs's Third Harmonic Bio position peaked at $1.2M in Q2 2025.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.